December 14, 2016
Kyowa Hakko Kirin said on December 13 that its Parkinson’s disease treatment istradefylline, which is sold under the Nouriast brand in Japan, failed to meet the primary endpoint in a PIII study conducted in North America and Europe. The placebo-controlled...read more